Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health...
-
Upload
john-spencer -
Category
Documents
-
view
218 -
download
2
Transcript of Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health...
![Page 1: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/1.jpg)
Introduction to PKPD Modelling – Applications
Joe Standing
June 2012UCL Institute of Child Health & Great Ormond
Street Hospital for Children, London
![Page 2: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/2.jpg)
Mycophenolate in Lupus
• Mycophenolic acid: selective noncompetitive inhibitor of ionosine 5’-monophosphate dehydrogenase (IMPDH)
• Blocking this depletes lymphocyte guanosine triphosphate
![Page 3: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/3.jpg)
Mycophenolate in LupusSimplistic statistical analysis
What could model-based approach show?
![Page 4: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/4.jpg)
Summary
• Scaling Pharmacokinetics
• Empirical PKPD models– Accepted PK target– In-vitro correlations– Models of disease score
• Effect site models
• Mechanistic PKPD
• Disease Models
![Page 5: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/5.jpg)
Medicines in Children
• Unlicensed medicines– Prevalence: 36-67% (ICU 90%+) (Turner 1998)
Notterman 1986:
![Page 6: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/6.jpg)
Regulatory Perspective
• Legislation– FDA Modernisation Act 1997– EU Paediatric Medicines Regulation 2006
• All new medicines must be studied
• Old medicines can be licensed for children with appropriate studies
![Page 7: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/7.jpg)
“Children are not small adults”Kearns 2003
VS.
“Children are small adults”Tod 2008 and adults?
7
![Page 8: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/8.jpg)
A typical plot:
8
![Page 9: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/9.jpg)
“Children are small adults”
• CL often better correlated with BSA than wt (Cawford 1950)
• BMR correlated with wt0.75 (Kleiber 1947)
9
![Page 10: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/10.jpg)
“Children are small adults”
10
![Page 11: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/11.jpg)
Scaling in PK: Tod et al 2008
• MF = maturation function• OF = organ function
11
![Page 12: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/12.jpg)
Scaling in PK: Maturation
• Anderson 2010, Midazolam maturation
12
![Page 13: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/13.jpg)
Scaling in PK: Size
• Warfarin (Takanashi 2006)
![Page 14: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/14.jpg)
Scaling in PK: Size
• Size matters (Takanashi 2006)
Dose/weight (mg/kg) 0.06 0.06 0.06
![Page 15: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/15.jpg)
Summary
• Scaling Pharmacokinetics
• Empirical PKPD models– Accepted PK target– In-vitro correlations– Models of disease score
• Effect site models
• Mechanistic PKPD
• Disease Models
![Page 16: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/16.jpg)
Aim for accepted target PK
![Page 17: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/17.jpg)
Aim for accepted target PK
![Page 18: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/18.jpg)
Principles of antimicrobial PKPD
18
![Page 19: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/19.jpg)
In vitro PKPD
19
![Page 20: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/20.jpg)
20
![Page 21: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/21.jpg)
Principles of antimicrobial PKPD
21
![Page 22: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/22.jpg)
Clinical data: Cmax/MICRATE OF CLINICAL RESPONSE VS. CMAX/MIC RATIO
22
![Page 23: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/23.jpg)
Clinical data: AUC/MIC
23
![Page 24: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/24.jpg)
Clinical data: AUC/MIC
24
![Page 25: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/25.jpg)
Clinical data T>MIC
25
Clinical evidence lacking…
![Page 26: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/26.jpg)
Be careful …
26
![Page 27: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/27.jpg)
Methotrexate (MTX) PKPD
PD marker – disease score
AimsCharacterise MTX PK in osteosarcoma patientsPredict when concentration will fall below
0.2mcmol/LInvestigate relationship between MTX PK and
mucositis scores
![Page 28: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/28.jpg)
Treatment Schedule (EURAMOS 1)
![Page 29: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/29.jpg)
Raw PK Data
943 concentrations from 46 patients on up to 12 occasions
![Page 30: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/30.jpg)
Mucositis Scoring
WHO mucositis scale
0 1 2 3 4
None Soreness± erythema
Erythema,ulcers, andpatient canswallowsolid food
Ulcers withextensiveerythemaand patientcannotswallowsolid food
Mucositisto the extentthat alimentationis not possible
![Page 31: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/31.jpg)
PK VPC
![Page 32: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/32.jpg)
PD VPC
![Page 33: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/33.jpg)
PKPD Relationship
![Page 34: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/34.jpg)
Summary
• Scaling Pharmacokinetics
• Empirical PKPD models– Accepted PK target– In-vitro correlations– Models of disease score
• Effect site models
• Mechanistic PKPD
• Disease Models
![Page 35: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/35.jpg)
Remifentanil PKPD in infants
Remifentanil used to decrease mean arterial pressure (MAP) during craniofacial surgery
Aim:Describe PKPD relationship with remifentanil
and MAP
![Page 36: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/36.jpg)
Data
7 infants (0.3-1y; 6.6-9.6kg)
6 had rich (3 samples/min) PD data
PD data during 1st half hour
PK data during whole operation (before and 5min after changes in rate)
![Page 37: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/37.jpg)
Remifentanil Raw DataIndividual plots (Run 104)
[PKF == 1]
Time
Ob
serv
atio
ns
/ Pre
dic
tion
s
5
10
15
20
25
30
0 50 100 150 200 250
ID:1
0 50 100 150 200 250
ID:2
0 50 100 150 200 250
ID:3
0 50 100 150 200 250
ID:4
0 50 100 150 200 250
ID:5
0 50 100 150 200 250
ID:6
0 50 100 150 200 250
ID:7
DV IPRE PRED
Individual plots (Run 104)[PKF == 0]
Time
Ob
serv
atio
ns
/ Pre
dic
tion
s
30
40
50
60
70
80
0 5 10 15 20
ID:1
0 5 10 15 20
ID:2
0 5 10 15 20
ID:4
0 5 10 15 20
ID:5
0 5 10 15 20
ID:6
0 5 10 15 20
ID:7
DV IPRE PRED
PK Data: Remifentanyl concentration vs time (min)
PD Data: MAP vs time (min)
![Page 38: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/38.jpg)
PD Model
Individual plots (Run 104)[PKF == 0]
Time
Ob
serv
atio
ns
/ Pre
dic
tion
s
30
40
50
60
70
80
0 5 10 15 20
ID:1
0 5 10 15 20
ID:2
0 5 10 15 20
ID:4
0 5 10 15 20
ID:5
0 5 10 15 20
ID:6
0 5 10 15 20
ID:7
DV IPRE PRED
![Page 39: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/39.jpg)
Remifentanil Results
Final model - Sigmoidal Emax
Target concentration for 30% MAP reduction = 14ng/mL
b.) Emax Model
20
30
40
50
60
70
80
90
100
20 30 40 50 60 70 80 90 100
Individual predicted MAP (mmHg)
Ob
serv
ed
MA
P (
mm
Hg
)
a.) Linear Model
20
30
40
50
60
70
80
90
100
20 30 40 50 60 70 80 90 100
Individual predicted MAP (mmHg)
Ob
serv
ed
MA
P (
mm
Hg
)
c.) Sigmoidal Emax Model (final)
20
30
40
50
60
70
80
90
100
20 30 40 50 60 70 80 90 100
Individual predicted MAP (mmHg)
Ob
serv
ed
MA
P (
mm
Hg
)
![Page 40: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/40.jpg)
Individual PD Fits
b.) Subject 1
20
30
40
50
60
70
80
0 1 2 3 4
Time (min)
MA
P (
mm
Hg
)
b.) Subject 2
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6 7 8 9 10 11 12
Time (min)
MA
P (
mm
Hg
)
b.) Subject 4
20
25
30
35
40
45
50
55
60
65
70
0 1 2 3 4 5 6 7 8 9
Time (min)
MA
P (
mm
Hg
)
0
2
4
6
8
10
12
14
16
18
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 190
2
4
6
8
10
12
14
16
18
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 240
2
4
6
8
10
12
14
16
0 1 2 3 4 5
b.) Subject 5
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Time (min)
MA
P (
mm
Hg
)
b.) Subject 6
20
30
40
50
60
70
80
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time (min)
MA
P (
mm
Hg
)
b.) Subject 7
20
25
30
35
40
45
50
55
60
65
0 1 2 3 4 5
Time (min)
MA
P (
mm
Hg
)
![Page 41: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/41.jpg)
Defined Concentration/Effect Relationship
![Page 42: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/42.jpg)
Summary
• Scaling Pharmacokinetics
• Empirical PKPD models– Accepted PK target– In-vitro correlations– Models of disease score
• Effect site models
• Mechanistic PKPD
• Disease Models
![Page 43: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/43.jpg)
Modelling hematological toxicity
• Relationship between drug exposure and myelosuppression
• Myelosuppression dose-limiting
• Typically: Logistic (Emax) model
0
1
2
3
4
5
6
7
8
9
10
0 5 10 15 20Time (Days)
Leu
kocyte
s (
x1
09/L
)
AUC
% D
ecre
ase a
t n
ad
ir
![Page 44: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/44.jpg)
CirculatingProliferative
MTT
Transit Transit Transitktrktrktrktr
Slope · Conc
Feedback = CirculatingCirc0
Model of myelosuppression:
![Page 45: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/45.jpg)
Estimated parameters - Leukocytes
*=Unbound concentrations
Circ0
(109/L)
IIVCirc0
(CV%)
MTT
(hours)
IIVMTT
(CV%)
Slope
(µM-1)
IIVSlope
(CV%)
Docetaxel 7.12 35 90.4 14 0.175 6.39 47
Paclitaxel 7.21 33 124 17 0.239 28.9* 42
Etoposide 7.07 39 135 14 0.189 0.0710 45
DMDC 7.50 34 123 22 0.121 0.660 44
CPT-11 8.10 26 125 31 0.147 0.892 40
Vinflunine 6.74 35 112 24 0.157 0.0020 40
![Page 46: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/46.jpg)
Neutrophil model example
• CP-690,550 new oral DMARD• Inhibitor of Janus kinase• T and Bcell depression, causes neutropenia• Phase 2a study, 264 subjects, placebo, 5, 15
and 30mg bd dosing
![Page 47: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/47.jpg)
Gupta et al PD model
Model simulation properties:Visual Predictive Check
![Page 48: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/48.jpg)
Gupta et al PD model
![Page 49: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/49.jpg)
Maintenance ALL treatment
![Page 50: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/50.jpg)
Maintenance ALL
• Prevents recurrence in sanctuary sites
• 3 monthly intrathecals
• Monthly: vinc, dex
• Weekly: MTX
• Daily: 6-MP
• Target neuts: 0.75 – 1.5 *109/L
![Page 51: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/51.jpg)
Retrospective data• 31 children, 2-13 y
![Page 52: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/52.jpg)
Research question
• Does dose affect neutrophil counts?
• How should doses be adjusted?
![Page 53: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/53.jpg)
Method
• Fitted Friberg model
• Drug effects as logistic decrease in proliferation
• Dexamethasone effect – increase Ktr
• Estimate baseline
![Page 54: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/54.jpg)
![Page 55: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/55.jpg)
![Page 56: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/56.jpg)
![Page 57: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/57.jpg)
Summary
• Scaling Pharmacokinetics
• Empirical PKPD models– Accepted PK target– In-vitro correlations– Models of disease score
• Effect site models
• Mechanistic PKPD
• Disease Models
![Page 58: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/58.jpg)
Diabetes Platform Models
![Page 59: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/59.jpg)
Extension to diabetes model
![Page 60: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/60.jpg)
Antiviral PKPD
60
![Page 61: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/61.jpg)
HIV viral load/CD4
![Page 62: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/62.jpg)
HIV viral load/CD4
![Page 63: Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d165503460f949eb7e5/html5/thumbnails/63.jpg)
Summary
• Scaling Pharmacokinetics
• Empirical PKPD models
• Effect site models
• Mechanistic PKPD
• Disease Models